文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

靶向BCMA的同种异体CAR-T细胞治疗复发/难治性多发性骨髓瘤:1期UNIVERSAL试验期中结果

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.
PubMed 文献 · Nat Med · 2023-01-23

UNIVERSAL 1期首次人体试验A部分评估ALLO-715(同种异体抗BCMA CAR-T)在43例复发/难治多发性骨髓瘤患者中递增剂量及含ALLO-647的清淋方案的安全性与疗效。≥3级不良事件见于38例(88.0%);细胞因子释放综合征24例(55.8%),≥3级1例(2.3%);神经毒性6例(14%),无≥3级事件;感染23例(53.5%),≥3级10例(23.3%)。总体24例(55.8%)有缓解。

要点

  • ALLO-715联合含ALLO-647清淋方案在复发/难治多发性骨髓瘤中总体缓解率55.8%。
  • 320×10^6 CAR+细胞联合氟达拉滨、环磷酰胺及ALLO-647清淋组(n=24)缓解率70.8%。
  • 细胞因子释放综合征55.8%,≥3级2.3%;神经毒性14%,无≥3级事件。

核心结论

  • 这些初步结果支持同种异体CAR-T细胞治疗多发性骨髓瘤的可行性与安全性。

研究设计与样本

  • 正在进行的首次人体1期UNIVERSAL试验A部分,评估ALLO-715在含抗CD52抗体ALLO-647清淋方案后递增剂量治疗复发/难治多发性骨髓瘤。
  • 共纳入43例复发/难治多发性骨髓瘤患者。
  • 主要目标为确定ALLO-715的安全性与耐受性及含ALLO-647清淋方案的安全性特征。
  • 关键次要终点为缓解率和缓解持续时间。

主要发现

  • ≥3级不良事件见于38例(88.0%)患者。
  • 细胞因子释放综合征见于24例(55.8%),其中≥3级1例(2.3%);神经毒性见于6例(14%),无≥3级事件。
  • 感染见于23例(53.5%),其中≥3级10例(23.3%)。
  • 总体24例(55.8%)有缓解。
  • 接受320×10^6 CAR+ T细胞联合氟达拉滨、环磷酰胺及ALLO-647清淋方案的患者(n=24)中,17例(70.8%)有缓解,包括11例(45.8%)达非常好的部分缓解或更好、6例(25%)达完全缓解/严格完全缓解;中位缓解持续时间为8.3个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ALLO-715 is a first-in-class, allogeneic, anti-BCMA CAR T cell therapy engineered to abrogate graft-versus-host disease and minimize CAR T rejection. We evaluated escalating doses of ALLO-715 after lymphodepletion with an anti-CD52 antibody (ALLO-647)-containing regimen in 43 patients with relapsed/refractory multiple myeloma as part A of the ongoing first-in-human phase 1 UNIVERSAL trial. Primary objectives included determination of the safety and tolerability of ALLO-715 and the safety profile of the ALLO-647-containing lymphodepletion regimen. Key secondary endpoints were response rate and duration of response. Grade ≥3 adverse events were reported in 38 (88.0%) of patients. Cytokine release syndrome was observed in 24 patients (55.8%), with 1 grade ≥3 event (2.3%) and neurotoxicity in 6 patients (14%), with no grade ≥3 events. Infections occurred in 23 patients (53.5%), with 10 (23.3%) of grade ≥3. Overall, 24 patients (55.8%) had a response. Among patients treated with 320 × 106 CAR+ T cells and a fludarabine-, cyclophosphamide- and ALLO-647-based lymphodepletion regimen (n = 24), 17 (70.8%) had a response including 11 (45.8%) with very good partial response or better and 6 (25%) with a complete response/stringent complete response. The median duration of response was 8.3 months. These initial results support the feasibility and safety of allogeneic CAR T cell therapy for myeloma.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Mailankody S, Matous JV, Chhabra S, et al. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med. 2023. PMID: 36690811. doi:10.1038/s41591-022-02182-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。